Revolution Medicines’ daraxonrasib hit 13.2 months median overall survival against 6.7 months for chemotherapy in the Phase III RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma. Revolution’s shares jumped 40%. The company earned a plenary slot at ASCO 2026, running May 29 through June 2 in Chicago.
Pancreatic cancer has a 13% five-year relative survival rate, and that number hasn’t meaningfully moved in decades. Daraxonrasib is an oral RAS inhibitor — the same mutations drive PDAC, non-small cell lung cancer and colorectal cancer. The ASCO plenary on Sunday will surface the toxicity picture: earlier data showed the vast majority of patients developed a rash, and around 30% had serious side effects. Investigator Meredith Pelster at Sarah Cannon Research Institute said understanding how to counsel patients on those side effects is what Sunday’s full dataset needs to deliver.
The second plenary headliner: HARMONi-6, Summit Therapeutics and Akeso’s China-only trial of PD-1/VEGF bispecific ivonescimab. At ESMO in October 2025, it posted median PFS of 11.14 months versus 6.9 months against tislelizumab plus chemotherapy in advanced squamous NSCLC. But more recent global trials didn’t clear PFS or overall survival marks, tempering expectations. Sunday’s overall survival readout is what determines whether ivonescimab can realistically challenge Keytruda globally.
If daraxonrasib’s toxicity profile proves manageable, it’s a RAS inhibitor race in NSCLC and colorectal cancer: same target, much larger markets. If HARMONi-6 delivers a big OS delta, it forces every oncology program built around PD-1 monotherapy to reconsider its position.
Both plenary readouts are scheduled for Sunday, May 31.
Sarah Chen